

**Corporate Sponsored Presentations**

Session Time (PDT)/ Location	Abstract #/Title/Lead Author	Type
<b>Saturday, October 21, 2023</b>		
Saturday, October 21, 2023 3:45 PM Sevilla Auditorium – Hall 9	<b>857 / Tucatinib SGTUC-017</b> Impact of baseline molecular alterations on the efficacy of tucatinib (TUC) plus trastuzumab (Tras) for HER2+, RAS WT metastatic CRC (mCRC) in MOUNTAINEER <b>Lead Author: J Strickler</b>	<b>Proffered Paper</b> (Oral Presentation)
<b>Sunday, October 22, 2023</b>		
Sunday, October 22, 2023 10:45 AM Sevilla Auditorium – Hall 9	<b>813 / Enfortumab vedotin EV-103 Cohort L</b> Study EV-103 Cohort L: perioperative treatment w/ enfortumab vedotin (EV) monotherapy in cisplatin (cis)-ineligible patients (pts) w/ muscle invasive bladder cancer (MIBC) <b>Lead Author: S Sridhar</b>	<b>Mini Oral Presentation</b>
Sunday, October 22, 2023 4:30 PM Madrid Auditorium – Hall 6	<b>LBA6 / Enfortumab vedotin EV-302</b> EV-302/KEYNOTE-A39: Open-label, randomized phase 3 study of enfortumab vedotin in combination with pembrolizumab (EV+P) ss chemotherapy (chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC) <b>Lead Author: T Powles</b>	<b>Presidential Symposium</b> (Oral Presentation)
Sunday, October 22, 2023 5:22 PM Madrid Auditorium – Hall 6	<b>LBA9 / Tisotumab vedotin innovaTV 301</b> innovaTV 301/ENGOT-cx12/GOG-3057: a randomized, open-label, phase 3 study of tisotumab vedotin vs investigator's choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer <b>Lead Author: I Vergote</b>	<b>Presidential Symposium</b> (Oral Presentation)
<b>Monday, October 23, 2023</b>		
Monday, October 23, 2023 9:00 AM – 5:00 PM Hall 8	<b>1914 / Tucatinib SGTUC-022</b> Phase 2 dose optimization results from MOUNTAINEER-02: a study of tucatinib, trastuzumab, ramucirumab, and paclitaxel for HER2+ gastroesophageal cancer (GEC) <b>Lead Author: M Tehfe</b>	<b>Poster Presentation</b>
Monday, October 23, 2023 5:10 PM Valencia Auditorium – Hall 10	<b>1546 / SGN-B7H4V SGNB7H4V-001</b> First-in-human study of SGN-B7H4V, a B7-H4-directed vedotin ADC, in patients with advanced solid tumors: preliminary results of a phase 1 study (SGNB7H4V-001) <b>Lead Author: C Perez</b>	<b>Mini Oral Presentation</b>

The safety and efficacy of these investigational compounds, or investigational uses of marketed products, have not been established. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

## IST Presentations

Session Time (PDT)/ Location	Abstract #/Title/Lead Author	Type
Saturday, October 21, 2023 Time TBD Location TBD	<b>387P / Disitamab vedotin</b> Efficacy and safety of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive and HER2-low expressing, locally advanced or metastatic breast cancer: a single-arm phase II study	<b>Poster Presentation</b>

The safety and efficacy of these investigational compounds, or investigational uses of marketed products, have not been established. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.